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The efﬁcacy and safety of vortioxetine, an antidepressant approved for the treatment of adults
with major depressive disorder (MDD), was studied in 11 randomized, double-blind, placebo-
controlled trials of 6/8 weeks' treatment duration. An aggregated study-level meta-analysis was
conducted to estimate the magnitude and dose-relationship of the clinical effect of approved
doses of vortioxetine (5–20 mg/day). The primary outcome measure was change from baseline
to endpoint in Montgomery–Åsberg Depression Rating Scale (MADRS) total score. Differences
from placebo were analyzed using mixed model for repeated measurements (MMRM) analysis,
with a sensitivity analysis also conducted using last observation carried forward. Secondary
outcomes included MADRS single-item scores, response rate (Z50% reduction in baseline
MADRS), remission rate (MADRS r10), and Clinical Global Impressions scores. Across the 11
studies, 1824 patients were treated with placebo and 3304 with vortioxetine (5 mg/day:
n=1001; 10 mg/day: n=1042; 15 mg/day: n=449; 20 mg/day: n=812). The MMRM meta-
analysis demonstrated that vortioxetine 5, 10, and 20 mg/day were associated with signiﬁcant
reductions in MADRS total score (Δ-2.27, Δ-3.57, and Δ-4.57, respectively; po0.01) versus
placebo. The effects of 15 mg/day (Δ-2.60; p=0.105) were not signiﬁcantly different from
placebo. Vortioxetine 10 and 20 mg/day were associated with signiﬁcant reductions in 10 of 10
MADRS single-item scores. Vortioxetine treatment was also associated with signiﬁcantly higher
rates of response and remission and with signiﬁcant improvements in other depression-related
scores versus placebo. This meta-analysis of vortioxetine (5–20 mg/day) in adults with MDDo.2016.03.007
hed by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
/by-nc-nd/4.0/).
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Major depressive disorder (MDD) is a challenging clinical
condition in which only about 30% to 40% of patients achieve
full remission with ﬁrst-line therapy of adequate duration
(Trivedi et al., 2006; Warden et al., 2007) and about one-third
of patients do not achieve remission even after therapy with
as many as four different antidepressants (Warden et al.,
2007). Furthermore, many antidepressants are associated with
side effects that limit their tolerability and reduce compliance
(Papakostas, 2010). The limitations of existing therapies have
led to calls for better treatment options for patients with MDD
(Rosenzweig-Lipson et al., 2007), many of whom experience
prolonged and recurrent depressive episodes (American
Psychiatric Association (APA), 2010).
Vortioxetine is an antidepressant that was approved in 2013
in the United States (US) for the treatment of adults with MDD
and in the European Union (EU) for the treatment of major
depressive episodes in adults. Vortioxetine differs from other
currently available antidepressants owing to its multimodal
activity within the central nervous system. In addition to
inhibiting the serotonin (5-HT) transporter (Bang-Andersen
et al., 2011), vortioxetine is an antagonist at 5-HT3, 5-HT7,
and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, and
an agonist at 5-HT1A receptors (Bang-Andersen et al., 2011;
Mork et al., 2012; Westrich et al., 2012). As of 1 March 2015, 23
phase 2/3 clinical trials of vortioxetine in MDD have been
completed with results reported (US National Institutes of
Health (NIH), 2015), including 11 short-term, randomized,
double-blind, parallel-group, placebo-controlled studies of up
to eight weeks' duration (Alvarez et al., 2012; Baldwin et al.,
2012; Boulenger et al., 2014; Henigsberg et al., 2012; Jacobsen
et al., 2015b; Jain et al., 2013; Mahableshwarkar et al., 2015a,
2013, 2015b; McIntyre et al., 2014; Takeda, 2013).
To date, four independent meta-analyses of vortioxetine
in patients with MDD have been published. Berhan and
Barker (2014) conducted a literature-based analysis focusing
on study-level data from seven peer-reviewed publications
of placebo-controlled studies using doses of 1 to 20 mg/day.
Pae et al. (2015) analyzed seven peer-reviewed publica-
tions, four congress abstracts, and one clinical study report
of studies using the doses of 1 to 20 mg/day. Meeker et al.
(2015) analyzed peer-reviewed publications for eight stu-
dies data from US Food and Drug Administration (FDA)
review documents, and www.ClinicalTrials.gov for another
3 studies with doses of 1 to 20 mg/day. All three
meta-analyses included non-therapeutic doses of vortioxe
tine (1 and 2.5 mg/day) and the vortioxetine trial in elderly
patients (Katona et al., 2012). One used the predeﬁned
primary endpoints, based on either the Montgomery–Åsberg
Depression Rating Scale (MADRS) or the Hamilton Depression
Rating Scale–24 item (HAM-D24) and all doses of vortioxetine
were collapsed (Pae et al., 2015). Another used the MADRS,based on either mixed model for repeated measurements
(MMRM) or analysis of covariance (ANCOVA), last observation
carried forward (LOCF), as input for the meta-analyses
(Meeker et al., 2015). Behzadifar et al. (2015) performed
a meta-analysis of only studies with vortioxetine 20 mg/day
and placebo groups (n=4) and results from each trial were
statistically combined using the Mantel–Haenszel random
effects model.
We have conducted an aggregated data (AD) meta-analysis
of vortioxetine clinical trials in MDD, using MMRM results from
each study based on MADRS total score as the primary
analysis, with a sensitivity analysis conducted using results
from ANCOVA, LOCF for missing data. This statistical plan was
chosen because it would provide the most consistent input to
the overall meta-analysis. The AD meta-analysis was
designed to estimate the magnitude and dose-dependent
effects of vortioxetine on depressive symptoms in patients
with MDD. Depressive symptoms were assessed using the
MADRS (Montgomery and Asberg, 1979) total score, MADRS
single-item scores, MADRS response, MADRS remission, and
the Clinical Global Impressions (CGI) (Guy, 1976) scores. The
AD meta-analysis was restricted to patients who where
treated with the approved therapeutic vortioxetine dosages
of 5 to 20 mg/day, in line with the doses approved in the US
and the EU (H. Lundbeck A/S, 2015; Takeda Pharmaceuticals
America Inc., 2014). The 15-mg/day dose, although only used
in three studies (two of which were conducted in the US),
was included for completeness.2. Experimental procedures
2.1. Short-term placebo-controlled vortioxetine
clinical trials in patients with MDD
The clinical development program for vortioxetine in MDD was
international in nature, with the studies conducted at multiple sites
within countries. The studies were designed, conducted, and reported
in accordance with the principles of the World Medical Association
Declaration of Helsinki and in compliance with the principles of the
International Conference on Harmonisation (ICH) guidelines for Good
Clinical Practice. The study sponsors (Takeda Development Center
Americas, Inc. and H. Lundbeck A/S) assumed overall responsibility for
the studies, including those in which monitoring was delegated to a
contract research organization.
This meta-analysis was limited to short-term (6 or 8 weeks),
double-blind, placebo-controlled, ﬁxed-dose studies evaluating vor-
tioxetine 5–20 mg in adults (aged 18–75 years) with MDD that have
been previously published in a public forum and have reported results
on the ClinicalTrials.gov database prior to 1 March 2015 (Alvarez et al.,
2012; Baldwin et al., 2012; Boulenger et al., 2014; Henigsberg et al.,
2012; Jacobsen et al., 2015b; Jain et al., 2013; Mahableshwarkar
et al., 2015a, 2013, 2015b; McIntyre et al., 2014; Takeda, 2013).
Table 1 provides a summary of treatment dosages, number of
participants in each dosage arm, treatment duration, and key MDD
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each trial, participants had to meet the criteria for a major depressive
episode, as described in the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), lasting at
least three months and be 18 to 75 years of age, inclusive. Additional
inclusion criteria included MADRS total scores of at least 22
(NCT00672620) (Mahableshwarkar et al., 2013), 30 (NCT00839423
(Alvarez et al., 2012) and NCT00672958 (Jain et al., 2013)), or 26
(all other studies). An additional eligibility requirement for a Clinical
Global ImpressionsSeverity of Illness (CGI-S) (Guy, 1976) score of at
least 4 was required for the NCT01140906 (Boulenger et al., 2014),
NCT01153009 (Mahableshwarkar et al., 2015b), NCT01163266
(Jacobsen et al., 2015b), and NCT01179516 (Mahableshwarkar et al.,
2015a) studies.
Based on the increase in placebo response and a decrease in
treatment response in clinical trials over the past 20 to 30 years, as
well as to address any potential issues of regionality or hetero-
geneity, two separate patient populations datasets were evaluated
in the AD meta-analysis – a total population analysis utilizing
aggregated study-level data from all 11 trials in adults and a second
which only utilizing data from the 6 trials conducted primarily
outside the US (NCT00839423, NCT00635219, NCT01140906,
NCT01422213, NCT01255787, and NCT00735709). The dedicated
trial with vortioxetine in elderly patients (NCT00811252 (Katona
et al., 2012)) was not included in any of the present meta-analyses,
as it only enrolled patients aged 65 years and above.
2.2. Clinical outcomes
The predeﬁned primary efﬁcacy endpoints in the individual studies
were either the MADRS total score, HAM-D24 (Williams, 2001) total
score, or a composite z-score of Digit Symbol Substitution Test
(DSST) and Rey Auditory Verbal Learning Test (RAVLT) score, with
the MADRS total score as a predeﬁned secondary endpoint in those
trials that utilized the HAM-D24 total score or DSST/RAVLTcomposite
score. Secondary efﬁcacy variables included MADRS response and
remission, and the CGI-S and Clinical Global Impressions Improve-
ment (CGI-I) (Guy, 1976) scores. In the 6-week studies
(NCT00839423 (Alvarez et al., 2012) and NCT00672958 (Jain
et al., 2013)), participants were examined every week from
Screening to Completion, for a total of eight scheduled visits. In
the 8-week studies, participants were examined every week from
Screening to Week 2, and thereafter every second week to
completion, for a total of nine scheduled visits.
2.3. Statistical analysis
The vortioxetine clinical development program utilized two different
methodologies for conducting primary statistical analyses – MMRM in
5 studies (NCT01140906 (Boulenger et al., 2014), NCT01422213
(McIntyre et al., 2014), NCT00735709 (Henigsberg et al., 2012),
NCT01153009 (Mahableshwarkar et al., 2015b), and NCT01179516
(Mahableshwarkar et al., 2015a)) with ANCOVA, LOCF utilized in
6 studies (NCT00839423 (Alvarez et al., 2012), NCT00635219 (Baldwin
et al., 2012), NCT01255787 (Takeda, 2013), NCT00672958 (Jain et al.,
2013), NCT00672620 (Mahableshwarkar et al., 2013), and NCT01163266
(Jacobsen et al., 2015b)). However, all studies have been analyzed using
both methodologies (data provided directly from study sponsors). In
order to provide the most reliable estimates of treatment effect, an
aggregated data (AD) meta-analytic approach based on study level
results using common methodology was chosen. The AD meta-analytic
approach was selected because it efﬁciently and robustly manages
heterogeneity of results over studies and avoids potentially misleading
results arising from not having all dosages in all studies. A random
effects AD meta-analytic approach was used to account for hetero-
geneity in the results between studies thus broadening the conﬁdence
interval (CI) for the meta-analysis compared to a ﬁxed effects model.The level of heterogeneity was expressed in terms of I2 (Higgins et al.,
2003), which describes the percentage of total variation of the
treatment effect across studies that is due to heterogeneity rather
than to chance.
For 7 of the 11 individual studies (not including NCT00672958 (Jain
et al., 2013), NCT00672620 (Mahableshwarkar et al., 2013),
NCT01422213 (McIntyre et al., 2014), and NCT00735709 (Henigsberg
et al., 2012)), as well as for this AD meta-analysis, the primary outcome
measure was deﬁned as the change from baseline in MADRS total score
at the end of the treatment period. MMRM has speciﬁc attributes suited
to the data structure of acute-phase neuropsychiatric clinical studies
and has been compared extensively to ANCOVA, LOCF methodology
(Siddiqui et al., 2009). Research based on actual data (Mallinckrodt
et al., 2004) as well as data simulation (Siddiqui et al., 2009) indicates
that, in many scenarios, analyses based on the MMRM provide estimates
that have less bias, as well as superior control over both type I (false
positive) and type II (false negative) errors. This makes the MMRM
analysis better suited for investigations of potential dose response
relations. In the current meta-analysis, results from ANCOVA, LOCF is
utilized as a separate sensitivity analysis to the analysis based on MMRM
results. Standard methodology for MMRM and ANCOVA, LOCF meta-
analysis was applied for each study (Armitage and Colton, 1998).
The MMRM model had a completely unstructured covariance matrix
and included terms for site, baseline score by visit interaction, and
treatment by visit interaction. The ANCOVA, LOCF sensitivity analysis
utilized treatment and site as ﬁxed factors and the baseline scale
score as a covariate. All analyses were performed on the Full Analysis
Set (FAS), which was previously deﬁned for each study.
Secondary endpoints in this meta-analysis were MADRS single-
item scores, MADRS response rate (deﬁned as a decline of at least
50% from baseline in MADRS total score), MADRS remission rate
(deﬁned as MADRS total score less than or equal to 10), CGI-S score,
and CGI-I score. The endpoints were analyzed using MMRM and
ANCOVA, LOCF (as described above) except for the MADRS response
and remission, where logistic regression was used to provide odds
ratios as input for the meta-analysis.
Results represent the least squares (LS) mean differences or odds
ratios versus placebo (95% CI). All statistical tests are two-sided with a
0.05 signiﬁcance level. The numbers needed to treat (NNTs) were
calculated as the reciprocal of the risk difference between vortiox-
etine and placebo. The 95% CIs for the NNTs were calculated as the
reciprocals of the limits from the 95% CIs for the risk differences.
Standardized effect sizes (SES; also referred to as standardized mean
differences), were interpreted as Cohen's d statistics.
An exploratory analysis of individual participant data (IPD),
often referred to as a pooled data meta-analysis, was also
conducted on the primary efﬁcacy variable of change from
baseline versus placebo in MADRS total score (LOCF) using a
random-effects modeling approach, acknowledging the poten-
tial bias of this analysis due to the comparison of dosages that
were only included in some of the studies to an overall placebo
population that includes patients from all studies. The IPD
approach has a tendency to produce conﬁdence intervals that
are too narrow and therefore the IPD analysis may be regarded
as a less conservative approach. Although IPD has been con-
sidered the “gold standard” for meta-analyses, research has
found relatively little difference in the summary level conclu-
sions drawn from IPD and AD when using the same pool of studies
and in the absence of confounding factors (Angelillo and Villari,
2003; Lyman and Kuderer, 2005; Mathew and Nordstrom, 1999;
Olkin and Sampson, 1996). Due to convergence issues, MMRM
modeling could not be performed using IPD.
3. Results
Figure 1 depicts a ﬂow diagram of study eligibility and
reasons for study exclusion. This AD meta-analysis of 11
Table 1 Summary characteristics of the 11 short-term, placebo-controlled studies of vortioxetine in patients with MDD included in the meta-analysis (FAS).
NCT identiﬁer Treatment period Dose mg/day (na) Key inclusion criteria for MDD Primary efﬁcacy endpoint Reference
NCT00839423 6 weeks VOR 5 (108) MADRS Z30 MADRS (Alvarez et al., 2012)
VOR 10 (100)
VEN 225 (112) MDE Z3 months
and o12 monthsPBO (105)
NCT00635219 8 weeks VOR 2.5 (155) MADRS Z26
MDE Z3 months
MADRS (Baldwin et al., 2012)
VOR 5 (155)
VOR 10 (151)
DUL 60 (149)
PBO (145)
NCT00735709 8 weeks VOR 1 (124) MADRS Z26
MDE Z3 months
HAM-D24 (Henigsberg et al., 2012)
VOR 5 (129)
VOR 10 (122)
PBO (128)
NCT01140906 8 weeks VOR 15 (149) MADRS Z26
CGI-SZ4
MDE 43 months recurrent
MADRS (Boulenger et al., 2014)
VOR 20 (151)
DUL 60 (146)
PBO (158)
NCT01153009 8 weeks VOR 15 (145) MADRS Z26
CGI-SZ4
MDE Z3 months recurrent
MADRS (Mahableshwarkar et al., 2015a)
VOR 20 (147)
DUL 60 (146)
PBO (153)
NCT01163266 8 weeks VOR 10 (154) MADRS Z26
CGI-SZ4
MDE Z3 months recurrent
MADRS (Jacobsen et al., 2015b)
VOR 20 (150)
PBO (155)
NCT01422213 8 weeks VOR 10 (193) MADRS Z26
MDE Z3 months recurrent
DSST and RAVLT composite (McIntyre et al., 2014)
VOR 20 (204)
PBO (194)
NCT01255787 8 weeks VOR 5 (142) MADRS Z26
CGI-SZ4
MDE Z3 months
MADRS (Takeda, 2013)
VOR 10 (147)
VOR 20 (149)
PBO (150)
NCT00672958 6 weeks VOR 5 (292) MADRS Z30
MDE Z3 months
HAM-D24 (Jain et al., 2013)
PBO (286)
NCT00672620 8 weeks VOR 2.5 (146) MADRS Z22
MDE Z3 months
HAM-D24 (Mahableshwarkar et al., 2013)
VOR 5 (153)
DUL 60 (149)
PBO (149)
NCT01179516 8 weeks VOR 10 (143) MADRS Z26
CGI-SZ4
MDE Z3 months recurrent
MADRS (Mahableshwarkar et al., 2015b)
VOR 15 (142)
PBO (149)
CGI-S: Clinical Global Impressions–Severity of Illness; DSST: Digit Symbol Substitution Test; DUL: duloxetine; HAM-D24: Hamilton Anxiety Rating Scale–24 item; MADRS: Montgomery–Åsberg
Depression Rating Scale; MDE: major depressive episode; PBO: placebo; RAVLT: Rey Auditory Verbal Learning Test; VEN: venlafaxine XR; VOR: vortioxetine.
an represents all randomized participants who took at least one dose of study medication and had at least one valid post-baseline measurement of the primary efﬁcacy variable.
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983Vortioxetine: A meta-analysis of randomized, placebo-controlled trialstrials included 1824 patients treated with placebo and 3304
treated with vortioxetine 5–20 mg/day (5 mg/day: n=1001;
10 mg/day: n=1042; 15 mg/day: n=449; 20 mg/day:
n=812) for duration of up to eight weeks. Summary demo-
graphic and baseline characteristics for participants in the
FAS are shown in Table 2. The placebo and vortioxetine
groups had similar characteristics, including moderate to
severe depression (as indicated by mean baseline MADRS
total scores of approximately 32) and mild to moderate
anxiety (as indicated by mean Hamilton Anxiety Rating
Scale total scores of approximately 20).3.1. MADRS total scores
In the individual studies of vortioxetine in patients with MDD, a
consistent dose relationship was seen demonstrating a greater
change from baseline in MADRS total score for each dosage
group. The meta-analysis supported this dose-dependent trend
(Figure 2). Speciﬁcally, in studies where different doses of
vortioxetine were investigated, the higher dose demonstrated
a greater treatment response from baseline. Seven of the 11
trials found evidence that at least one dosage of vortioxetine
treatment was associated with signiﬁcantly greater reductions
in mean MADRS total score versus placebo. The MMRM meta-
analysis (Figure 2A) showed that treatment with vortioxetine
was associated with signiﬁcantly greater reductions in meanFigure 1 PRISMA Flow Diagram for Study Inclusion. * ClinicalTria
depressive disorder (condition); completed (recruitment); results po
to 1 March 2015 (last updated) (US National Institutes of Health (NMADRS total score compared to placebo in patients receiving
5 mg (n=840, Δ 2.27 points, p=0.007), 10 mg (n=877, Δ
3.57 points, po0.001), and 20 mg (n=671, Δ 4.57 points,
po0.001) (FAS, MMRM). Although the 15-mg arm (n=344) had
a numerically greater reduction in mean MADRS total score
versus placebo (Δ 2.60 points), the difference was not
statistically signiﬁcant (p=0.105). Similar results were
obtained when the meta-analysis was performed using the
ANCOVA, LOCF method (Figure 2B); however, the dose rela-
tionship was less pronounced within individual studies with
more than one dose of vortioxetine. In the MMRM meta-
analysis of non-US studies, all vortioxetine dosage groups had
signiﬁcantly greater mean reductions in MADRS total scores
compared to placebo, with a more pronounced dose relation-
ship (vortioxetine 5 mg, n=476, Δ 3.20 points, p=0.001;
10 mg, n=630, Δ 4.24 points, po0.001; 15 mg, n=118, Δ
5.53 points, po0.001; 20 mg, n=437, Δ 5.41 points,
po0.001; FAS, MMRM). Heterogeneity was slightly lower in
the non-US meta-analysis for vortioxetine 5 mg and 10 mg but
higher for 20 mg compared to the overall meta-analysis (MMRM
and ANCOVA, LOCF), as demonstrated by the I2 value for
heterogeneity (Figure 2A and B).
The exploratory meta-analysis of MADRS total score using
IPD from all available clinical trials demonstrated a signiﬁcant
treatment response for all vortioxetine doses (5 mg, Δ 2.10
points, SE70.68, p=0.007; 10 mg, Δ 2.64 points, SE70.64,
po0.001; 15 mg, Δ 2.26 points, SE70.93, p=0.027; andls.gov search components: vortioxetine (intervention); major
sted (study results); phase 2 or 3 (phase); updated on or before
IH), 2015). PC: placebo-controlled.
Table 2 Summary of demographics, baseline characteristics, and baseline efﬁcacy parameters for patients included in the
meta-analysis of 11 short-term, placebo-controlled clinical studies of vortioxetine in patients with MDD (FAS).
Placebo
(N=1784)
Vortioxetine 5 mg
(N=989)
Vortioxetine 10 mg
(N=1028)
Vortioxetine 15 mg
(N=436)
Vortioxetine 20 mg
(N=800)
Age, years, mean
(SD)
44.0 (12.46) 44.1 (12.79) 44.9 (12.24) 44.9 (13.61) 44.7 (12.49)
Sex, female, n (%) 1146 (64.2) 644 (65.1) 696 (67.7) 300 (68.8) 528 (66.0)
Race, n (%)
Caucasiana 1454 (81.5) 752 (76.0) 812 (79.0) 360 (82.6) 648 (81.0)
Black 216 (12.1) 122 (12.3) 90 (8.8) 68 (15.6) 89 (11.1)
Asian 107 (6.0) 110 (11.1) 112 (10.9) 6 (1.4) 53 (6.6)
Otherb 7 (0.4) 5 (0.5) 14 (1.4) 2 (0.5) 10 (1.3)
BMI, kg/m2
Mean (SD) 28.5 (6.99) 27.9 (7.34) 27.5 (6.75) 29.2 (7.18) 28.0 (6.63)
Mean duration of
current MDE, n (%)
o24 weeks 855 (47.9) 494 (49.9) 565 (55.0) 194 (44.5) 377 (47.1)
Z24 weeks 929 (52.1) 495 (50.1) 459 (44.6) 242 (55.5) 423 (52.9)
Number of previous
MDEs
N 1613 802 914 436 753
Mean (SD) 2.7 (2.24) 2.8 (3.05) 2.6 (2.12) 2.7 (1.90) 2.7 (2.30)
Region, n (%)
United States 925 (51.8) 445 (45.0) 332 (32.3) 287 (65.8) 333 (41.6)
Non-United States 859 (48.2) 544 (55.0) 696 (67.7) 149 (34.2) 467 (58.4)
MADRS total score
Mean (SD) 32.1 (4.00) 32.4 (4.04) 32.3 (4.03) 32.5 (4.09) 31.8 (3.88)
CGI-S total score
Mean (SD) 4.7 (0.68) 4.8 (0.70) 4.7 (0.67) 4.7 (0.61) 4.6 (0.62)
HAM-A total scorec
Mean (SD) 19.7 (6.32) 20.1 (6.23) 20.6 (6.46) 19.4 (6.11) 18.9 (6.12)
BMI: body mass index; CGI-S: Clinical Global Impressions–Severity of Illness, HAM-A: Hamilton Anxiety Rating Scale, MADRS:
Montgomery–Åsberg Depression Rating Scale, MDE: major depressive episode
aCaucasian (or white, including Hispanic)
bOther: including American Indian/Alaska Native, Native Hawaiian (or other Paciﬁc Islander), and missing.
cStudy NCT01422213 did not measure HAM-A as an outcome measure; therefore, n-values for the HAM-A analysis set are: 1586
(placebo), 983 (vortioxetine 5 mg), 830 (10 mg), 436 (15 mg), and 596 (20 mg).
M.E. Thase et al.98420 mg, Δ 3.71 points, SE70.73, po0.001; LS means, LOCF),
with a pattern similar to that seen in the primary (MMRM) and
sensitivity (ANCOVA, LOCF) analyses. As expected, the IPD
produced smaller standard errors, and therefore smaller and
less conservative conﬁdence intervals.3.2. MADRS single-item scores
The MMRM meta-analysis of individual MADRS single-item
scores showed that vortioxetine 10 and 20 mg/day were
associated with signiﬁcantly greater mean reductions from
baseline in MADRS single-item scores versus placebo, with a
similar overall dose relationship as with the reduction in
mean MADRS total score (Figure 3). The meta-analysis of
MADRS single-item scores using ANCOVA, LOCF yielded
similar results and overall dose-relationship to the MMRM
meta-analysis (Supplemental Figure 1).3.3. Response rates
The percentage of patients in each trial achieving a
responding to treatment (deﬁned as at least a 50% reduction
in MADRS total score from baseline to the end of treatment)
is shown in Figure 4A. The 5-, 10-, and 20-mg vortioxetine
groups had signiﬁcantly higher rates of response compared
to the placebo group (placebo, n=655/1783 [36.7%]; vor-
tioxetine 5 mg, n=496/989 [50.2%], p=0.002; 10 mg,
n=501/1026 [48.8%], po0.001; 15 mg, n=202/436 [46.3%],
p=0.080; 20 mg, n=412/799 [51.6%], po0.001; FAS, LOCF;
p-values are from the odds ratios using logistic regression).
When only considering clinical trials conducted outside the
US, the meta-analysis was signiﬁcant for all vortioxetine
doses (placebo, n=200/547 [36.6%]; vortioxetine 5 mg,
n=221/402 [55.0%], po0.001; 10 mg, n=223/389 [57.3%],
po0.001; 15 mg, n=85/149 [57.0%], po0.001; 20 mg,
n=93/151 [61.6%], po0.001; FAS, LOCF).
Figure 2 A. Difference from Placebo in Change from Baseline in MADRS Total Score (FAS, MMRM) B. Difference from Placebo in
Change from Baseline in MADRS Total Score (FAS, ANCOVA, LOCF).
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Figure 3 Difference from Placebo in Change from Baseline in MADRS Single-Item Scores (FAS, MMRM).
M.E. Thase et al.9863.4. Remission rates
The percentage of patients in each trial achieving remis-
sion, deﬁned as a MADRS total score of less than or equal to
10 at the end of the treatment period, is shown in
Figure 4B. The vortioxetine 10 mg (po0.001) and 20 mg
(po0.05) groups had signiﬁcantly higher remission rates
than did the placebo group (placebo, n=425/1783 [23.8%];
vortioxetine 5 mg, n=304/989 [30.7%], p=0.188; 10 mg,
n=310/1026 [30.2%], po0.001; 15 mg, n=125/436
[28.7%], p=0.189; 20 mg, n=258/799 [32.3%], p=0.002;
FAS, LOCF; p-values are from the odds ratios using logistic
regression). In the meta-analysis of clinical trials con-
ducted outside the US, vortioxetine demonstrated a sig-
niﬁcant effect on remission in all treatment groups
(placebo, n=130/547 [23.8%]; vortioxetine 5 mg, n=148/
402 [36.8%], p=0.029; 10 mg, n=139/389 [35.7%],
p=0.043; 15 mg, n=52/149 [34.9%], p=0.002; 20 mg,
n=58/151 [38.4%], po0.001; FAS, LOCF).3.5. CGI-I and CGI-S scores
The MMRM meta-analysis of CGI-I and CGI-S supported the
results of the overall analysis of the MADRS total score. The
meta-analysis of the CGI-I demonstrated a dose-related clinical
improvement similar to that seen in the individual clinical trials
when compared to placebo (vortioxetine 5 mg, n=839, Δ
0.28, po0.001; 10 mg, n=876, Δ 0.42, po0.001; 15 mg,
n=344, Δ 0.29, p=0.165; 20 mg, n=670, Δ 0.50, p=0.002;
FAS, MMRM). The analysis of the CGI-I in clinical studies
conducted outside the US demonstrated a clinical improvement
for all doses, similar to that seen in the analysis of the MADRS
total score (vortioxetine 5 mg, n=475, Δ 0.36, po0.001;
10 mg, n=630, Δ 0.52, po0.001; 15 mg, n=118, Δ 0.69,
po0.001; 20 mg, n=437, Δ 0.67, p=0.005; FAS, MMRM)
(Figure 5). The meta-analysis using ANCOVA, LOCF yielded
results similar to the meta-analysis using MMRM, but the dose
relationship was less pronounced (results not shown) due to an
increase in Type 1 error.
Figure 4 A. Response Rates (Deﬁned as Z50% Decrease in MADRS) at Week 6/8 (FAS, LOCF) B. Remission Rates (Deﬁned as MADRS
r10) at Week 6/8 (FAS, LOCF).
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M.E. Thase et al.988The MMRM meta-analysis of the CGI-S demonstrated a similar
dose-related response to the response seen in the individual
clinical trials (vortioxetine 5 mg, n=838, Δ 0.29, p=0.012;
10 mg, n=877, Δ 0.46, po0.001; 15 mg, n=344, Δ 0.36,
p=0.128; 20 mg, n=670, Δ 0.55, p=0.001; FAS, MMRM), with
a greater clinical response seen in non-US clinical studies
(vortioxetine 5 mg, n=474, Δ 0.42, p=0.004; 10 mg, n=630,
Δ 0.60, po0.001; 15 mg, n=118, Δ 0.82, po0.001; 20 mg,
n=437, Δ 0.76, po0.001; FAS, MMRM) (Figure 6). The meta-
analysis using ANCOVA, LOCF yielded results similar to the
meta-analysis using MMRM, but the dose relationship was less
pronounced (results not shown), again due to an increase in
Type 1 error.4. Discussion
The current meta-analysis of aggregated study-level data
includes 11 short-term placebo-controlled trials in adults
using efﬁcacy data of the approved dose range of vortiox-
etine, 5–20 mg/day. Vortioxetine was found to be an efﬁca-
cious antidepressant, as shown by the reduction of the
MADRS total and single-item scores, and supported by a
larger proportion of responders and remitters compared to
placebo and by improvements on the global clinical impres-
sion scales (CGI-I and CGI-S). For patients treated with
vortioxetine 10 mg/day (the recommended starting dose),Figure 5 Difference from Placebo in Change frothe mean difference from placebo in change from baseline
in MADRS total score was 3.57 points; a reduction of at
least 2 points on the MADRS total score versus placebo is
usually considered clinically meaningful (Melander et al.,
2008; Montgomery and Moller, 2009).
For most outcome measures, the effects of vortioxetine
therapy showed a general dose-dependent trend, with
improvements in depression-related outcomes increasing
as vortioxetine dose increased from 5 mg/day to 10 mg/
day and again to 20 mg/day. The dose relationship was
observed in both the MMRM and ANCOVA, LOCF meta-
analyses – as well as the exploratory IPD analysis – and
was more pronounced when using MMRM, particularly within
individual studies. The individual studies that utilized the
higher doses of vortioxetine also demonstrated a greater
difference to placebo on the MADRS total score, which was
conﬁrmed by the meta-analysis. Furthermore, when con-
ducting the meta-analysis using data from the six non-US
studies, the dose response effect was more pronounced
compared to the meta-analysis of all 11 studies. Although
results for vortioxetine 15 mg/day deﬁed this trend in the
meta-analysis, this dose had the smallest sample size (as it
was only utilized in three clinical trials) with substantially
wider CIs compared to the other doses, and two of the three
clinical trials were conducted exclusively in the US (region-
ality discussed later on). The efﬁcacy of vortioxetine
treatment in the individual studies and the meta-analysism Baseline in CGI-I Total Score (FAS, MMRM).
Figure 6 Difference from Placebo in Change from Baseline in CGI-S Total Score (FAS, MMRM).
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(Katona et al., 2012); in that trial, vortioxetine 5 mg/day
for eight weeks was associated with mean reductions in
MADRS total score and rates of remission and response that
were signiﬁcantly better than placebo.
The lack of a clear dose–response relationship in the
evaluation of overall response rate and remission rate
should also be noted, highlighting the lack of sensitivity of
these secondary assessments to identify a clinically mean-
ingful change over time. Although response remission rates
were predeﬁned in the overall statistical testing hierarchy,
the individual clinical trials were not speciﬁcally designed
to detect differences to placebo in response or remission
rates; rather, the studies were powered to analyze overall
change from baseline, a more time-sensitive measure of
clinical response. Furthermore, the dose response was also
less pronounced partly due to the LOCF being applied and
partly due to the dichotomization involved in the responder
deﬁnition, where a large amount of information is lost.
This AD meta-analysis supports the ﬁndings of the four
published meta-analyses of vortioxetine (Behzadifar et al.,
2015; Berhan and Barker, 2014; Meeker et al., 2015; Pae
et al., 2015), which identiﬁed a therapeutic and clinically
relevant beneﬁt of vortioxetine for patients with MDD. Each
of the previous meta-analyses of vortioxetine used study-
level data from peer-reviewed clinical trial reports, con-
gress presentations, the FDA evaluation of vortioxetine, orfrom ClinicalTrials.gov. In addition to the similar results of
antidepressant effects, these studies identiﬁed a substantial
level of heterogeneity in the meta-analyses. A number of
methodological differences between the previous meta-
analyses and that reported here can be identiﬁed. Three
of the previous meta-analyses included all doses of vortiox-
etine (1, 2.5, 5, 10, 15, and 20 mg/day) and included the
vortioxetine trial in elderly patients (Berhan and Barker,
2014; Meeker et al., 2015; Pae et al., 2015). In one of the
meta-analyses, the input used was a combination of both
MMRM and ANCOVA, LOCF results, depending on which
analysis was used as the primary efﬁcacy analysis in the
individual trial (Meeker et al., 2015); one meta-analysis only
included seven trials (Berhan and Barker, 2014), and one
used both MADRS total score and HAM-D24 total score as the
endpoint using LOCF and with all doses of vortioxetine
collapsed (Pae et al., 2015). In addition, two of the previous
meta-analyses also compared the antidepressant effect of
vortioxetine directly to that of the active references used in
six of the trials (Meeker et al., 2015; Pae et al., 2015). One
meta-analysis utilized a mix of MMRM and ANCOVA, LOCF to
evaluate only trials evaluating vortioxetine 20 mg/day
(Behzadifar et al., 2015). In contrast to the four previous
meta-analyses of vortioxetine (Behzadifar et al., 2015;
Berhan and Barker, 2014; Meeker et al., 2015; Pae et al.,
2015), this aggregated meta-analysis utilized robust and
consistent statistical methodology to evaluate clinical data
M.E. Thase et al.990from all available placebo-controlled studies of vortioxetine
in adult patients with moderate to severe MDD.
The observation of a dose relationship in the current
meta-analysis is in contrast to one of the previous meta-
analyses, which did not ﬁnd a dose relationship. The
methodological differences between the previous meta-
analysis and the current one may have contributed to the
differences in conclusions on whether a dose relationship is
present. For example, the analysis by Meeker et al. (2015)
also included the 1-and 2.5-mg doses and inconsistently
used MMRM or ANCOVA, LOCF values as input to the analysis.
It has been reported that the use of ANCOVA, LOCF may
mask the presence of a dose relationship, which may be
identiﬁed if using MMRM (Preskorn, 2008; Siddiqui et al.,
2009). In addition, Meeker et al. (2015) utilized a statistical
output from a meta-regression analysis as the main deter-
minant of dose–response, with p40.05 resulting in the
conclusion of no dose relationship for response to treat-
ment. To accurately determine if a dose relationship is
present, multiple factors must be taken into consideration,
with results of the individual studies as well as those of the
meta-analysis taken into consideration. The observation of
a dose relationship for vortioxetine 5–20 mg/day is relevant
from a therapeutic and clinical perspective, as this has not
been reported for other antidepressants.
This meta-analysis centers on the comparison between
vortioxetine and placebo in the 11 individual studies and
does not evaluate differences between vortioxetine and the
active references (duloxetine and venlafaxine XR). The
results of the active references can be found in the
publications for the individual studies. In two of the
previous meta-analyses of the vortioxetine data, direct
comparisons between vortioxetine and the active reference
were included (Meeker et al., 2015; Pae et al., 2015). Direct
comparison of vortioxetine and the active reference is not
appropriate, as the individual studies were not designed or
powered to enable this comparison. Rather, the rationale
for including an active reference in these studies was for
the internal validation of the study design (i.e., assay
sensitivity). To evaluate the efﬁcacy of vortioxetine relative
to another antidepressant would require a study that is
speciﬁcally designed for that purpose, that is, an active-
comparator study (Jacobsen et al., 2015a; Montgomery
et al., 2014; Wang et al., 2015). In addition, in the six
studies that include an active reference, patients were
excluded – for ethical reasons – if they had known hyper-
sensitivity or a history of lack of response to previous
treatment with the active reference, which introduces the
potential for bias in favor of the active reference (ICH,
2000; Jin et al., 2013; Perlis et al., 2010).
The results of this meta-analysis are consistent with those
seen in the individual trials, which identiﬁed a dose-
dependent efﬁcacy of vortioxetine for depression-related
outcomes. However, some of the vortioxetine dosage groups
(5–20 mg/day) in individual trials failed to show signiﬁcant
beneﬁt of treatment versus placebo, consistent with other
trials of effective antidepressants, especially in recent
decades (Khin et al., 2011). Given that other effective
approved antidepressants have encountered difﬁculties
demonstrating efﬁcacy (even in well-designed placebo-con-
trolled clinical trials) (Khin et al., 2011), it is perhaps not
surprising that clinical trials with vortioxetine have also hadmixed success. Various explanations for failed antidepres-
sant trials have been proposed, although studies have not
identiﬁed a consistent cause or set of causes (Dunlop et al.,
2012; Khan et al., 2010; Khin et al., 2011). Analyses into
reasons of non-consistency have not been investigated, but
differences in clinical trial setting and geographic location
may have inﬂuenced the success or failure of speciﬁc trials.
The trials included in the current meta-analysis used
differing MADRS baseline total scores as entry criteria. This
difference might be expected to lead to differing outcomes,
as patients with higher MADRS total scores (hence worse
depression) may present a greater therapeutic opportunity.
However, there was no consistent trend relating the entry
criteria to the magnitude or signiﬁcance of vortioxetine
effects on MADRS total score during treatment, even at
higher doses. Furthermore, although the entry criteria
differed across the trials, the baseline MADRS total scores
were similar.
Clinical study results included in meta-analyses are usually
heterogeneous, which is also observed in the vortioxetine
clinical development program, despite the very similar study
design across the studies (Armitage and Colton, 1998).
Variation in responses was identiﬁed in this meta-analysis,
as well as in previous meta-analyses of the vortioxetine trials
(Behzadifar et al., 2015; Berhan and Barker, 2014; Meeker
et al., 2015; Pae et al., 2015). This type of heterogeneity can
be introduced due to, for example, regional differences and
differences in clinical practice. Because of this potential
source of variability, it was relevant to analyze the effect of
vortioxetine based on the trials conducted outside the US in
addition to the meta-analysis of all trials. The incidence of
heterogeneity is slightly less pronounced with the lower
doses of vortioxetine when the meta-analysis only includes
trials conducted outside the US, as compared to the meta-
analysis of all trials.
Several factors have been suggested to affect the outcome
of MDD trials, including the setting (academic versus non-
academic), the number of active treatment arms, the
number of assessments, type of raters used (centralized
versus non-centralized), inﬂation of depression rating scores
at inclusion, number of previous treatment episodes, pre-
vious treatments used, treatment compliance, and region
(Dunlop et al., 2012; Jain et al., 2013; Khan et al., 2003;
Kobak et al., 2010; Mallinckrodt et al., 2011; Mundt et al.,
2007; Shen et al., 2008; Vieta et al., 2011). In addition, there
has been a steady decline in the antidepressant-placebo
difference in clinical studies (Khin et al., 2011), with this
decline appearing to be particularly pronounced in studies
conducted in the US, thought primarily due to the higher
placebo response (Vieta et al., 2011). None of these factors
have been identiﬁed as clearly contributing to the outcome
of the clinical trials with vortioxetine. No single causative
factor can be isolated to explain the differences between
5 studies conducted in the US and those conducted outside
the US. It appears, however, that issues around study
conduct, including patient selection, adherence to the pro-
tocol, and investigational medicinal product regimen, are
critical. This analysis shows that trials conducted outside the
US were more likely to report signiﬁcant vortioxetine efﬁcacy
than were US trials. Other studies have reported important
differences between the US and other countries with regard
to patient and disease characteristics, diagnostic and clinical
991Vortioxetine: A meta-analysis of randomized, placebo-controlled trialspractices, and the conduct of clinical trials (Chang et al.,
2008; Khin et al., 2011; Niklson and Reimitz, 2001). For
example, studies NCT01140906 and NCT01153009 were iden-
tical in study design, both in terms of duration, doses,
inclusion and exclusion criteria, and study endpoints, but
with the difference that NCT01140906 was conducted outside
the US and NCT01153009 was conducted exclusively in the US
(Boulenger et al., 2014; Mahableshwarkar et al., 2015b). The
non-US NCT01140906 study was a positive study, with vor-
tioxetine 15 and 20 mg/day separating from placebo and with
a relatively large standardized effect sizes. This is in contrast
to the US study NCT01153009, where only the 20-mg/day
dose separated from placebo and with a lower standardized
effect size than the non-US study. The explanation for
differences in the outcomes of vortioxetine trials is not
entirely understood, but a population-based pharmacoki-
netic/pharmacodynamic analysis of the vortioxetine clinical
development program identiﬁed that 15% of patients in the
US phase 3 trials of vortioxetine had lower and more variable
plasma drug concentrations than did patients on correspond-
ing vortioxetine doses in the non-US phase 3 trials (3–5%)
(Areberg et al., 2013). In contrast, patients in phase 1 trials,
where compliance is monitored more closely, had similar
plasma drug concentrations regardless of study location. Such
differences could explain the greater difﬁculty in demon-
strating a signiﬁcant treatment effect of vortioxetine in US
trials compared with non-US trials.
This meta-analysis of aggregated study-level data from 11
randomized, placebo-controlled, short-term studies with
vortioxetine (5–20 mg/day) in adult MDD patients supports
the efﬁcacy proﬁle demonstrated in the individual studies,
with an overall increasing effect size associated with
increasing dose, not seen with other antidepressants. The
broad clinical efﬁcacy proﬁle of vortioxetine – as demon-
strated by the effect on the primary endpoint of change
from baseline in MADRS total score – is supported by the
effect on other depression endpoints as well as overall
clinical improvement.
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